Diyabet tani ve tedavi rehberi 2017-12x21cm indd

KAYNAKÇA

---

147
TÜRKDİAB Diyabet Tanı ve Tedavi Rehberi 2017
KAYNAKÇA
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, 
Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin 
P-H for the DASH- Sodium Collaborative Research Group. Effects on blood 
pressure of reduced dietary sodium and the Dietary Approaches to Stop 
Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10
Schmieder RE: Hypertension and diabetes what are the pros to treating 
early surrogates? Diabetes Care 2009; 32(Suppl 2): S294-7
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, 
Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular 
disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31
Sever PS, Dahlof B, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, 
Caufield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen 
M, O’Brien E, Ostergren J, for the ASCOT investigators: Prevention of 
coronary and stroke events with atorvastatin in hypertensive subjects who 
have average or lower-than- average cholesterol concentratons, in the 
Anglo- Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT- 
LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149 -58
Snowling NJ, Hopkins WG: Effects of different modes of exercise training 
on glucose control and risk factors for complications in type 2 diabetic 
patients. A meta-analysis. Diabetes Care 2006; 29: 2518-27
The Action to Control Cardiovascular Risk in Diabetes Study Group: 
Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 
2008; 358: 2545-59
The ALLHAT offcers and coordinators for the ALLHAT Collaborative 
Research Group: Major outcomes in moderately hypercholesterolemic, 
hypertensive patients randomized to pravastatin vs usual care: the 
Antihypertensive and Lipid- Lowering Treatment to prevent Heart Attack 
Trial (ALLHAT-LLT). JAMA 2002; 288: 2998 -3007
The DCCT Research Group: Weight gain associated with intensive 
therapies in the Diabetes Control and Complications Trial. Diabetes Care, 
1998; 111: 567-73
Third Report of the Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults. Adult Treatment Panel III. National 
Cholesterol Education Program. JAMA 2001; 285: 2486-97
Triplitt C: How to initiate, titrate, and intensify insulin treatment in type 2 
diabetes. US Pharm 2007; 32(10): 10-6

---

TÜRKDİAB Diyabet Tanı ve Tedavi Rehberi 2017
148
Tuomilehto J, Lindstrom J, Eriksson JG, Vale TT, Hamalainene H, Ilanne-
Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas 
M, Saliminen V, Uusi- tupa M, for the Finnish Diabetes Prevention Study 
Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among 
subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
T.C. Sağlık Bakanlığı Halk Sağlığı Kurumu. Türkiye Diyabet Programı 
2015-2020. Ankara, 2014. Ulusal Diyabet Konsensus Grubu ve TBD 
Genel Sağlık Ağız-Diş Sağlığı İş Birliği Geliştirme Komisyonu. Diyabet 
Dişhekimi Klinik Rehberi 2015. İstanbul. Pasifik Reklam
UK Prospective Diabetes Study 7: Response of fasting plasma glucose to 
diet therapy in newly presenting type II diabetic patients, UKPDS Group. 
Metabolism, 1990; 39(9): 905-12
UK Prospective Diabetes Study Group: Intensive blood-glucose control 
with sulphonylureas or insulin compared with conventional treatment and 
risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 
1998; 352: 837-53
UK Prospective Diabetes Study Group: Intensive blood-glucose control 
with metformin on complications in overweight patients with type 2 
diabetes (UKPDS 34) Lancet 1998; 352: 854-65
United Kingdom Prospective Diabetes Study Group: Tight blood pressure 
control and risk of macrovascular and microvascular complications in type 
2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13
Vinik A, Mehrabyan A, Colen L, Boulton A: Focal entrapment neuropathies 
in diabetes. Diabetes Care 2004; 27: 1783–8
Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic 
neuropathy. Diabetes Care. 2003; 26(5): 1553-79
Walker M, Marshall SM, Alberti KGMM: Clinical aspects of diabetic 
ketoacidosis. Diabetes Metab Rev 1989; 5: 651–63
Wenk RE, Yoho S, Bengzan A. Pseudohypoglycemia with monoclonal 
immunoglobulin M [letter]. Arch Pathol Lab Med. 2005;129:454-455.
WHO and IDF. Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycemia: report of a WHO/IDF consultation. World 
Health Organisation, Geneva 2006
Wild S, Roglic G, Green A, Sicree R, King H: Global Prevalence of 
Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes 
Care 2004; 27(5): 1047–1053
KAYNAKÇA